177 Lu-DOTATATE Therapy in Patients with Metastatic Neuroendocrine Tumours: Toxicity, Survival, and Prognostic Factors (EANM 2026) - Sep 29, 2026 - Abstract #EP-0411; "177Lu-DOTATATE therapy is effective and safe in patients with metastatic NETs, with manageable haematological toxicity. The Ki-67 index and prior treatment history are key prognostic factors, while completion of the full treatment course and somatostatin analogue maintenance are independently associated with improved survival outcomes."
Biomarker • Clinical • Metastases • Gastric Cancer • Hematological Disorders • Hepatology • Neuroendocrine Tumor • Neutropenia • Oncology • Solid Tumor
|
|
E. Karol Vera; A. Piñeiro Donis; L. Cagua Ruiz; E. Dominguez Polanco; T. Aroui Luquin; R. Sanchez Sanchez
|